Skip to main content
. 2025 Apr 16;51:119. doi: 10.1186/s13052-025-01961-5

Table 1.

Prevalence of symptoms’ persistence at three months in the whole study population and according to treatments subsequently prescribed

All
1250
MEP + LF
152
LF
18
MEP
9
P value
Mean Age (y) 6.8 7.1 6.9 7.1 > 0.05
Persisting Symptoms
Low grade fever 8 (0.6) 2 (1.3) 2 (11.1) 0 > 0.05
Anosmia 11 (0.9) 5 (3.3) 1 (5.6) 1 (11.1) > 0.05
Dysgeusia 11 (0.9) 4 (2.6) 2 (11.1) 0 > 0.05
Chronic Cough 16 (1.3) 5 (3.3) 1 (5.6) 0 > 0.05
Dyspnea with mild efforts 77 (6.2) 38 (25) 9 (50) 3 (33.3) > 0.05
Tachycardia 20 (1.6) 12 (7.9) 1 (5.6) 1 (11.1) > 0.05
Joint Pains 31 (2.5) 14 (9.2) 5 (27.8) 1 (11.1) > 0.05
Muscle Pains 53 (4.2) 28 (18.4) 8 (44.4) 0 > 0.05
Chronic Headache 69 (5.5) 43 (28.3) 8 (44.4) 2 (22.2) > 0.05
Chronic gastrointestinal problems 56 (4.5) 30 (19.7) 4 (22.2) 1 (11.1) > 0.05
Rashes 14 (1.1) 7 (4.6) 1 (5.6) 1 (11.1) > 0.05
Easily fatigued with mild efforts 15 (1.2) 6 (3.9) 1 (5.6) 0 > 0.05
Concentrations and Memory difficulties 31 (2.5) 19 (12.5) 2 (11.1) 0 > 0.05
Unusual Fatigue 162 (13) 93 (61.2) 11 (61.1) 3 (33.3) > 0.05
Chest pain 29 (2.3) 14 (9.2) 2 (11.1) 1 (11.1) > 0.05

MEP: Multi-Element Product

LF: lactoferrin